Free tool
FAERS Monitor: Tradjenta
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201280 or its brand name (Tradjenta, Linagliptin). Reports on generic versions are filed under their own applications.
Reports
18,487
Serious
13,056
71% of reports
Hospitalization
7,085
Death reported
1,717
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,385
- diarrhoea1,322
- nausea1,241
- fatigue1,098
- dyspnoea1,060
- off label use1,019
- dizziness997
- vomiting976
- acute kidney injury860
- malaise843
- headache810
- pruritus788
- arthralgia778
- pyrexia758
- pain702
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2010 | 2 |
| 2011 | 206 |
| 2012 | 698 |
| 2013 | 589 |
| 2014 | 818 |
| 2015 | 1,202 |
| 2016 | 1,404 |
| 2017 | 1,204 |
| 2018 | 1,281 |
| 2019 | 1,380 |
| 2020 | 1,169 |
| 2021 | 1,238 |
| 2022 | 1,636 |
| 2023 | 1,906 |
| 2024 | 1,457 |
| 2025 | 1,270 |
| 2026 | 1,026 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose increasedSignal | 1,385 | 8.4 | 8.0 | 9,061 |
| acute kidney injurySignal | 860 | 6.4 | 6.0 | 3,940 |
| pyrexiaSignal | 758 | 2.5 | 2.3 | 688 |
| vomitingSignal | 976 | 2.4 | 2.2 | 783 |
| pruritusSignal | 788 | 2.3 | 2.2 | 610 |
| diarrhoeaSignal | 1,322 | 2.3 | 2.2 | 1,035 |
| dizzinessSignal | 997 | 2.3 | 2.1 | 728 |
| malaiseSignal | 843 | 2.2 | 2.0 | 554 |
| dyspnoeaSignal | 1,060 | 2.1 | 2.0 | 653 |
| arthralgiaSignal | 778 | 2.1 | 2.0 | 474 |
| nausea | 1,241 | 1.8 | 1.7 | 444 |
| fatigue | 1,098 | 1.6 | 1.5 | 259 |
| headache | 810 | 1.5 | 1.4 | 125 |
| off label use | 1,019 | 1.3 | 1.2 | 84 |
| pain | 702 | 1.3 | 1.2 | 50 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.